FX.co ★ Astellas Pharma H1 Profit Rises; Lifts FY24 Outlook

Astellas Pharma Inc. (ALPMY) announced a significant increase in its first-half profits, reaching 73.51 billion yen, a 105.3% rise compared to the previous year. The basic earnings per share climbed to 41.06 yen, representing a 105.7% growth. The company's core operating profit also saw a substantial jump of 36.2%, totaling 183.05 billion yen, with basic core earnings per share increasing by 29.0% to 78.62 yen.

During the first six months, Astellas recorded a revenue of 935.62 billion yen, marking a 22.0% increase from the previous year.

In light of these results, the company has revised its fiscal 2024 forecast upwards. It now estimates a core profit of 220.0 billion yen, a projected basic core earnings per share of 122.90 yen, and anticipates revenue to reach 1.8 trillion yen. Additionally, the basic earnings per share are expected to be 27.93 yen.